The article highlights the earnings report of Ligand Pharmaceuticals Inc. for the fourth quarter, marked by significant figures:
In contrast to the previous year's Q4 loss of $17.49 million, Ligand Pharmaceuticals Inc. reported earnings of $18.19 million for the same period this year. Earnings per share (EPS) also demonstrated a stark improvement, shifting from a negative $1.04 last year to a positive $1.03 this year.
Excluding individual items affecting the bottom line, Ligand Pharmaceuticals Inc. posted adjusted earnings of $24.41 million, or $1.38 per share for the quarter. These figures overperformed analyst projections, which expected $0.66 per share.
However, a drop was observed in the company's overall revenue for Q4, down by more than half from $50.38 million in the last year's quarter to $28.10 million this year.
